Clinical Trial Update: Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating the effect of nicotinic acid on cardiovascular risk indices in women with polycystic ovary syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycystic Ovary Syndrome

Drugs mentioned

• Nicotinic acid (niacin)

Snippet

Sponsor: Hull University Teaching Hospitals NHS Trust | Conditions: Polycystic Ovary Syndrome | Phase 4 | Status: COMPLETED